GEODE-II: Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Low-Dose Ribavirin QD in Patients with Genotype 1a Chronic Hepatitis C Virus Infection without Cirrhosis

被引：0
|
作者：
Poordad, Fred [1 ]
Sedghi, Shahriar [2 ]
Pockros, Paul J. [12 ]
Ravendhran, Natarajan [3 ]
Reindollar, Robert [4 ]
Lucey, Michael R. [5 ]
Epstein, Michael S. [6 ]
Bank, Leslie [7 ]
Bernstein, David E. [8 ]
Trinh, Roger [9 ]
Krishnan, Preethi [9 ]
Pilot-Matias, Tami [9 ]
Polepally, Akshanth R. [9 ]
Pothacamury, Rajvineeth K. [9 ]
Unnebrink, Kristina [10 ]
Martinez, Marisol [9 ]
Nelson, David R. [11 ]
机构：
[1] Univ Texas Hlth Sci Ctr San Antonio, Texas Liver Inst, San Antonio, TX 78229 USA
[2] Mercer Univ, Sch Med, Med & Surg, Macon, GA 31207 USA
[3] Digest Dis Associates, Baltimore, MD USA
[4] Piedmont Healthcare Carolinas Ctr Liver Dis, Statesville, NC USA
[5] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Gastroenterol Hepatol, Madison, WI USA
[6] Digest Disorders Associates, Anne Arundel Med Ctr, Annapolis, MD USA
[7] Reg Clin Res Inc, Endwell, NY USA
[8] Hofstra Northwell Sch Med, Manhasset, NY USA
[9] AbbVie Inc, N Chicago, IL USA
[10] AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany
[11] Univ Florida, Dept Med, Gainesvillle, FL USA
[12] Scripps Clin, Div Gastroenterol Hepatol, La Jolla, CA 92037 USA
来源：
HEPATOLOGY | 2016年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
872
引用
收藏
页码：431A / 432A
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of paritaprevir/ritonavir, ombitasvir and dasabuvir plus/minus ribavirin for treatment of hepatitis C virus genotype 1b compensated cirrhosis in patients aged 70 years or older
    Trifan, A.
    Prelipcean, C. C.
    Gheorghe, L.
    Curescu, M. G.
    Brisc, C.
    Bataga, S.
    Miftode, E.
    Arama, V.
    Chiriac, S. A.
    Cuciureanu, T.
    Sporea, I.
    Goldis, A.
    Popescu, A.
    Iacob, S.
    Cojocariu, C.
    Stefanescu, G.
    Girleanu, I.
    Mihai, C.
    Ciortescu, I.
    Stanciu, C.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S284 - S285
  • [32] Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2
    Rockstroh, Juergen K.
    Orkin, Chloe
    Viani, Rolando M.
    Wyles, David
    Luetkemeyer, Anne F.
    Lazzarin, Adriano
    Soto-Malave, Ruth
    Nelson, Mark R.
    Bhagani, Sanjay R.
    Klinker, Hartwig H. F.
    Rizzardini, Giuliano
    Girard, Pierre-Marie
    Tural, Cristina
    Shulman, Nancy S.
    Mobashery, Niloufar
    Hu, Yiran B.
    Fredrick, Linda M.
    Pilot-Matias, Tami
    Trinh, Roger
    Gane, Edward
    OPEN FORUM INFECTIOUS DISEASES, 2017, 4 (03):
  • [33] Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir Plus Ribavirin in Daily Practice Hepatitis C Virus Genotype 1-or 4-Infected Patients with Compensated Cirrhosis
    Petta, Salvatore
    Marzioni, Marco
    Russo, Pierluigi
    Aghemo, Alessio
    Alberti, Alfredo
    Ascione, Antonio
    Antinori, Andrea
    Bruno, Raffaele
    Bruno, Savino
    Chirianni, Antonio
    Gaeta, Giovanni B.
    Giannini, Edoardo G.
    Merli, Manuela
    Messina, Vincenzo
    Montilla, Simona
    Perno, Carlo F.
    Puoti, Massimo
    Raimondo, Giovanni
    Rendina, Maria
    Ceccherini-Silberstein, Francesca
    Villa, Erica
    Zignego, Anna Linda
    Pani, Luca
    Craxi, Antonio
    HEPATOLOGY, 2016, 64 : 448A - 448A
  • [34] Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials
    Mensing, Sven
    Eckert, Doerthe
    Sharma, Shringi
    Polepally, Akshanth R.
    Khatri, Amit
    Podsadecki, Thomas J.
    Awni, Walid M.
    Menon, Rajeev M.
    Dutta, Sandeep
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (03) : 527 - 539
  • [35] Real-world efficacy and safety of ombitasvir, paritaprevir/r plus dasabuvir plus ribavirin in genotype 1b patients with hepatitis C virus cirrhosis
    Preda, Carmen M.
    Popescu, Corneliu P.
    Baicus, Cristian
    Voiosu, Theodor A.
    Manuc, Mircea
    Pop, Corina Silvia
    Gheorghe, Liana
    Sporea, Ioan
    Trifan, Anca
    Tantau, Marcel
    Tantau, Alina
    Ceausu, Emanoil
    Proca, Doina
    Constantinescu, Ileana
    Ruta, Simona M.
    Diculescu, Mircea M.
    Oproiu, Alexandru
    LIVER INTERNATIONAL, 2018, 38 (04) : 602 - 610
  • [36] Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan
    Atsukawa, Masanori
    Tsubota, Akihito
    Toyoda, Hidenori
    Takaguchi, Koichi
    Nakamuta, Makoto
    Watanabe, Tsunamasa
    Tada, Toshifumi
    Tsutsui, Akemi
    Ikeda, Hiroki
    Abe, Hiroshi
    Kato, Keizo
    Uojima, Haruki
    Ikegami, Tadashi
    Asano, Toru
    Kondo, Chisa
    Koeda, Mai
    Okubo, Tomomi
    Arai, Taeang
    Iwashita-Nakagawa, Ai
    Itokawa, Norio
    Kumada, Takashi
    Iwakiri, Katsuhiko
    HEPATOLOGY RESEARCH, 2019, 49 (04) : 369 - 376
  • [37] Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study (vol 2, pg 427, 2017)
    Petta, S.
    Marzioni, M.
    Russo, P.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (06): : E3 - E3
  • [38] Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis
    Chun-Hsien Chen
    Chien-Hung Chen
    Chih-Lang Lin
    Chun-Yen Lin
    Tsung-Hui Hu
    Shui-Yi Tung
    Sen-Yung Hsieh
    Sheng-Nan Lu
    Rong-Nan Chien
    Chao-Hung Hung
    I-Shyan Sheen
    Scientific Reports, 9
  • [39] Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease
    Lawitz, Eric
    Gane, Edward
    Cohen, Eric
    Vierling, John
    Agarwal, Kosh
    Hassanein, Tarek
    Mantry, Parvez S.
    Pockros, Paul J.
    Bennett, Michael
    Kemmer, Nyingi
    Morelli, Giuseppe
    Zha, Jiuhong
    Wang, Deli
    Shulman, Nancy S.
    Cohen, Daniel E.
    Reddy, K. Rajender
    KIDNEY INTERNATIONAL REPORTS, 2019, 4 (02): : 257 - 266
  • [40] Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin for Hepatitis C Virus Genotype 4 Patients
    Abdel-Moneim, Adel
    Aboud, Alaa
    Abdel-Gabbar, Mohamed
    Zanaty, Mohamed
    Ramadan, Mohamed
    DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (05) : 1341 - 1347
12345